L'Oreal CEO notes impact of GLP-1 drugs on beauty sales

L'Oreal CEO Nicolas Hieronimus stated that the rising use of GLP-1 weight loss drugs is influencing consumer behavior within the beauty and skin care sectors. The company is monitoring how these medications affect purchasing patterns as part of a broader shift in the wellness market. Management identified the trend as a significant factor for the business to track moving forward. Market participants are observing how the company adjusts its product strategy in response to changing consumer habits linked to weight loss treatments.